Major Increase of Quetiapine Steady-State Plasma Concentration Following Co-Administration of Clarithromycin: Confirmation of the Pharmacokinetic Interaction Potential of Quetiapine

The modern, atypical antipsychotic quetiapine is increasingly being used in the treatment of schizophrenia. Here, we report a case of a 32-year-old male patient with schizoaffective disorder who reached a markedly increased plasma concentration of quetiapine upon co-administration of clarithromycin. As a consequence he developed severely impaired consciousness and respiratory depression requiring intensive care surveillance. We provide evidence for a potent inhibition of quetiapine metabolism mediated by clarithromycin leading to a markedly reduced apparent oral clearance and a substantially prolonged terminal elimination half-life. Hence, titration of a quetiapine maintenance dose guided by therapeutic drug monitoring is recommended whenever clarithromycin is co-administered.

References

• 1 Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M. et al . The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
• 2 Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine.  Life Sci. 1998;  62 135-142
• 3 DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.  Clin Pharmacokinet. 2001;  40 509-522
• 4 Frahnert C, Rao ML, Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring.  J Chromatogr B Analyt Technol Biomed Life Sci. 2003;  794 35-47
• 5 Gerlach M, Hunnerkopf R, Rothenhofer S, Libal G, Burger R, Clement HW. et al . Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.  Pharmacopsychiatry. 2007;  40 72-76
• 6 Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.  Br J Clin Pharmacol. 2006;  61 58-69
• 7 Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I. et al . Therapeutic monitoring of new antipsychotic drugs.  Ther Drug Monit. 2004;  26 156-160
• 8 Pessina A, Turlizzi E, Bonomi A, Guizzardi F, Cavicchini L, Croera C. et al . In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU).  Pharmacopsychiatry. 2006;  39 20-22
• 9 Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.  Eur J Clin Pharmacol. 2006;  62 203-208
• 10 Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly.  Br J Clin Pharmacol. 2008;  65 98-109
• 11 Spina E, Leon J de. Metabolic drug interactions with newer antipsychotics: a comparative review.  Basic Clin Pharmacol Toxicol. 2007;  100 4-22
• 12 Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment.  Prog Neuropsychopharmacol Biol Psychiatry. 2000;  24 521-533

Correspondence